Codexis

About

Codexis is a biosciences company applying synthetic chemistry technologies to create improved versions of small molecule therapeutics.

Redwood City,California,United States
51 - 100
http://www.codexis.com

Highlights

Details

Last Funding Type: Series D
Last Funding Money Raised: $37M
Industries: Biotechnology,Chemical,Sustainability
Founded date: Jan 1, 2002
Number Of Employee: 51 - 100
Operating Status: Active
Stock Symbol: nasdaq:CDXS

Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis’ technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceutical firms using Codexis’ technology, products and services in their manufacturing process development.
Codexis creates its products by applying its CodeEvolver® directed evolution technology platform, which introduces genetic mutations into microorganisms.
Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$240M

Codexis has raised a total of $240M in funding over 2 rounds. Their latest funding was raised on Dec 2, 2020 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 2, 2020	Post-IPO Equity	$75M	—	—	—	Detail
Jun 20, 2019	Post-IPO Equity	$50M	1	Casdin Capital	—	Detail
Apr 30, 2010	IPO	$78M	—	—	—	Detail
Aug 14, 2006	Series D	$37M	5	EDBI	—	Detail

Investments

Number of Investments

Number of Lead Investments

3

1

Codexis has made 3 investments. Their most recent investment was on Mar 29, 2022, when seqWell raised $7M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Mar 29, 2022 seqWell	Series C	$7M	Biotechnology	Yes
Mar 15, 2022 Molecular Assemblies	Series B	$25.80M	Biotechnology	—
Apr 15, 2021 Molecular Assemblies	Series A	$11.80M	Biotechnology	—

Investors

Number of Lead Investors

Number of Investors

2

6

Codexis is funded by 6 investors. Casdin Capital and EDBI are the most recent investors.

Investor Name	Lead Investor	Funding Round
Casdin Capital	Yes	Post-IPO Equity
EDBI	Yes	Series D
Chevron Technology Ventures	—	Series D
CMEA Capital	—	Series D
Maxygen	—	Series D
Pequot Capital	—	Series D